Sanofi’s MS drugs get double boost in Europe

LONDON (Reuters) – Sanofi’s hopes in the multiple sclerosis market received a double boost on Friday as the European regulator backed an injectable treatment and adopted a more positive stance toward a pill for the neurodegenerative disease. The European Medicines Agency said it was recommending Lemtrada, Sanofi’s biggest MS drug hope, for relapsing-remitting MS, ending a quarter-century development saga for the injectable treatment. …